Healthcare >> CEO Interviews >> January 10, 2001
JOSEPH COOK, JR. has been Chairman of the Board and Chief Executive
Officer of Amylin Pharmaceuticals, Inc. since March 1998. Prior to such
time, he had served as a Board member and a consultant to the company
since 1994. Mr. Cook is also a Director of Dura Pharmaceuticals, Inc., a
specialty respiratory pharmaceutical and pulmonary drug delivery
company, and Nabi, a research- and development-driven biopharmaceutical
company that makes and markets products for people with life-threatening
conditions. Mr. Cook is a founder and serves as Chairman of the Board of
Microbia, Inc., a privately held biotechnology company. Mr. Cook is also
a founder of Clinical Products, Ltd., Life Science Advisors, LLC,
Cambrian Associates, LLC, and Mountain Ventures, Inc. Mr. Cook retired
as a Group Vice President of Eli Lilly and Company in 1993 after more
than 28 years of service. Mr. Cook received a BS in Engineering from the
University of Tennessee. Profile
Mr. Cook: Amylin was founded in 1987 following the discovery that a
second hormone, amylin, is produced by the beta cells
